戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  glomeruli is also elevated in patients with membranous nephropathy.
2  and segmental glomerulosclerosis (FSGS) and membranous nephropathy.
3 mmune deposits in glomeruli of patients with membranous nephropathy.
4 erlying disease and seems to be greatest for membranous nephropathy.
5 diseases, with highest induction observed in membranous nephropathy.
6 omerulonephritis, and severe skin lesions or membranous nephropathy.
7 anomalies play a role in the pathogenesis of membranous nephropathy.
8 lie the loss of podocyte barrier function in membranous nephropathy.
9 eymann nephritis (PHN), a rat model of human membranous nephropathy.
10 ce active Heymann nephritis (HN), a model of membranous nephropathy.
11 Heymann nephritis (HN), a rat model of human membranous nephropathy.
12  glomerulonephritis and less frequently with membranous nephropathy.
13 tients met the criteria for NSAID-associated membranous nephropathy.
14 AID intake should be sought in patients with membranous nephropathy.
15 hamide regimen is the first-line therapy for membranous nephropathy.
16 nditions including inflammation, cancer, and membranous nephropathy.
17  detectable in ~75% of patients with primary membranous nephropathy.
18  may serve as a novel therapeutic target for membranous nephropathy.
19 hropathy, fibrillary glomerulonephritis, and membranous nephropathy.
20 n and therapeutic targeting in patients with membranous nephropathy.
21 romote immune dysregulation and, ultimately, membranous nephropathy.
22 uniquely present within the biopsy tissue in membranous nephropathy.
23 (PLA2R1) is the major autoantigen in primary membranous nephropathy.
24 ainst PLA2R in drug development programs for membranous nephropathy.
25 for serologic evaluation of NELL1-associated membranous nephropathy.
26 itope spreading" determines the prognosis of membranous nephropathy.
27 een made in the discovery of autoantigens in membranous nephropathy.
28 ew window onto the humoral aspect of primary membranous nephropathy.
29 cyclophosphamide regimen in the treatment of membranous nephropathy.
30 that underlie the pathophysiology of primary membranous nephropathy.
31 ed with malignancy than other known types of membranous nephropathy.
32 thway and induced podocyte injury in primary membranous nephropathy.
33 ng, immunologic, THSD7A-associated, model of membranous nephropathy.
34 s nephritis and within rare cases of primary membranous nephropathy.
35 peutic intervention in patients with primary membranous nephropathy.
36 A2R1) is the major autoantigen in idiopathic membranous nephropathy.
37 toantigen in 70% of patients with idiopathic membranous nephropathy.
38 y showed phospholipase A 2 receptor-negative membranous nephropathy.
39 S variants, in minimal change disease, or in membranous nephropathy.
40 he UPS depended on oxidative modification in membranous nephropathy.
41 imal-change disease and a low correlation in membranous nephropathy.
42 d human glomerular diseases, particularly in membranous nephropathy.
43 rtant advances regarding the pathogenesis of membranous nephropathy.
44 R) is the major target antigen in idiopathic membranous nephropathy.
45 R) are sensitive and specific for idiopathic membranous nephropathy.
46 dict response to treatment with rituximab in membranous nephropathy.
47 l segmental glomerulosclerosis (2/4), and/or membranous nephropathy (1/4) but no definitive features
48   Here, we describe a patient with recurrent membranous nephropathy 13 days after kidney transplantat
49 oliferative glomerulonephritis (GN), 18; and membranous nephropathy, 16.
50        Of 125 patients identified with early membranous nephropathy, 29 were taking NSAIDs at the tim
51 e and 252 presumed patients with FSGS [40%], membranous nephropathy [40%], and minimal change disease
52                                   Idiopathic membranous nephropathy, a common form of the nephrotic s
53 n the prominent expression of FHR-5 in human membranous nephropathy, a disease in which complement ac
54  (18-75 years) with biopsy-proven idiopathic membranous nephropathy, a plasma creatinine concentratio
55 n and cancer and is the major autoantigen in membranous nephropathy, a rare but severe autoimmune kid
56 g a large cohort of patients with idiopathic membranous nephropathy according to a restrictive treatm
57 steroid-sensitive nephrotic syndrome or with membranous nephropathy after transplantation had low lev
58                        Recurrence of primary membranous nephropathy after transplantation occurs in u
59               However, in some patients with membranous nephropathy and crescents, the crescentic les
60   For the subset of patients with idiopathic membranous nephropathy and deteriorating excretory renal
61 n for end-stage renal disease resulting from membranous nephropathy and diabetic nephropathy.
62               In nephrotic diseases, such as membranous nephropathy and FSGS, persistent injury often
63  and HLA-D loci in 248 patients with primary membranous nephropathy and identified two independent si
64 pressive therapy in patients with idiopathic membranous nephropathy and nephrotic syndrome.
65 rt of 117 Caucasian patients with idiopathic membranous nephropathy and nephrotic-range proteinuria u
66          We randomly assigned 74 adults with membranous nephropathy and proteinuria >3.5 g/d to ritux
67                Crescents are rare in primary membranous nephropathy and thus suggest another underlyi
68 and nephrotic syndrome (minimal change/FSGS, membranous nephropathy, and C3 glomerulopathies).
69 in membrane nephropathy, lupus nephritis and membranous nephropathy, and correlated with estimated gl
70 and fibrosis, IgA nephropathy and idiopathic membranous nephropathy, and kidney transplantation.
71 (PLA(2)R1) are found in 80% of patients with membranous nephropathy, and previous studies described t
72 most prevalent circulating autoantibodies in membranous nephropathy are against phospholipase A2 rece
73 he two antigens associated with drug-induced membranous nephropathy are neural epidermal growth facto
74 nical syndromes associated with drug-induced membranous nephropathy are similar in that proteinuria r
75 e glomerulonephritis and another patient had membranous nephropathy as the cause of end-stage renal d
76 and podocyte MC5R appears to protect against membranous nephropathy, as demonstrated by its necessity
77 been made in our understanding of idiopathic membranous nephropathy, as well as treatment of this dis
78 t research investigations into mechanisms of membranous nephropathy associated with gold salts, penic
79 e 1 (NELL1) is the second leading antigen in membranous nephropathy, associated with malignancy, cert
80 ide polymorphisms (SNPs) at risk for primary membranous nephropathy at each locus.
81 (St-Cp) therapy for patients with idiopathic membranous nephropathy at high risk of progression to ES
82         Then we investigated whether primary membranous nephropathy at-risk variants were associated
83  autoimmune kidney disease; however, primary membranous nephropathy autoantigens remained elusive unt
84  is a resurgence of interest in drug-induced membranous nephropathy because of the widespread availab
85                                        Human membranous nephropathy biopsy samples showed podocyte st
86  - was induced in minimal change disease and membranous nephropathy, but not focal segmental glomerul
87 om such deposits in patients with idiopathic membranous nephropathy, but not in those with lupus memb
88 anous lupus nephritis and in 2.0% of primary membranous nephropathy cases.
89 A2R is the target of the autoimmune disease, membranous nephropathy, characterised by production of a
90                              In experimental membranous nephropathy, complement C5b-9-induces glomeru
91 given sheep anti-Fx1A to induce experimental membranous nephropathy; control rats received normal she
92 gmental glomerulosclerosis, minimal changes, membranous nephropathy, diffuse mesangial sclerosis and
93                                      De novo membranous nephropathy (dnMN) is an uncommon immune comp
94 r antigen discovery in malignancy-associated membranous nephropathy examining immune complexes eluted
95 rmal growth factor-like 1 (NELL1)-associated membranous nephropathy following lipoic acid supplementa
96 ndings have transformed our understanding of membranous nephropathy from that of an idiopathic diseas
97 r cohort, 15 of 154 patients with idiopathic membranous nephropathy had circulating autoantibodies to
98                       Thus, NELL1-associated membranous nephropathy has a unique histopathology chara
99                                Patients with membranous nephropathy have an increased risk of maligna
100       A majority of patients with idiopathic membranous nephropathy have antibodies against a conform
101                   About 3%-5% of adults with membranous nephropathy have autoantibodies directed agai
102        Up to 80% of patients with idiopathic membranous nephropathy have non-complement-fixing IgG4 a
103 rulosclerosis (HR, 0.80; 95% CI, 0.77-0.82), membranous nephropathy (HR, 0.88; 95% CI, 0.83-0.93), me
104  nephropathy (HRa, 0.74; 95% CI, 0.59-0.92), membranous nephropathy (HRa, 0.47; 95% CI, 0.29-0.75), a
105 disease, focal segmental glomerulosclerosis, membranous nephropathy, IgA nephropathy, antineutrophil
106 ase were primary FSGS, diabetic nephropathy, membranous nephropathy, immunoglobulin A nephropathy, an
107                Most patients with idiopathic membranous nephropathy (IMN) have IgG4 autoantibodies ag
108 1) is the major target antigen in idiopathic membranous nephropathy (iMN).
109 the autoimmune glomerular disease idiopathic membranous nephropathy (IMN).
110           In summary, this case of recurrent membranous nephropathy in a graft suggests that circulat
111 rapy has demonstrated potential in improving membranous nephropathy in human patients.
112 phritis is an experimental model that mimics membranous nephropathy in humans, wherein the glomerular
113  in seven patients, diabetic nephropathy and membranous nephropathy in one patient, and death due to
114 sive Heymann nephritis model of experimental membranous nephropathy in rats.
115 al of 35 patients treated with rituximab for membranous nephropathy in two distinct cohorts.
116 peutic advances for patients with idiopathic membranous nephropathy, including antibody inhibition th
117 ed podocyte foot-process architecture in rat membranous nephropathy, indicating disease-modifying eff
118  immune deposits in patients with idiopathic membranous nephropathy, indicating that PLA(2)R is a maj
119                                              Membranous nephropathy is a common cause of adult nephro
120                                      Primary membranous nephropathy is a common cause of adult-onset
121                                              Membranous nephropathy is a common cause of nephrotic sy
122                                              Membranous nephropathy is a disease that affects the fil
123                                      Primary membranous nephropathy is a leading cause of adult nephr
124                                              Membranous nephropathy is an autoimmune disease that res
125                                   Idiopathic membranous nephropathy is an autoimmune disease.
126 pports the emerging evidence that idiopathic membranous nephropathy is an autoimmune disease.
127                                              Membranous nephropathy is an autoimmune kidney disease c
128                                      Primary membranous nephropathy is an autoimmune kidney disease;
129                             The diagnosis of membranous nephropathy is based on the presence of granu
130                                              Membranous nephropathy is characterised by the depositio
131       It is concluded that hypofiltration in membranous nephropathy is the consequence of a biphasic
132 the target antigen for malignancy-associated membranous nephropathy is unknown.
133                       A third distinct type, membranous nephropathy, is rare in children.
134                                              Membranous nephropathy leads to end-stage renal disease
135                          Patients with lupus membranous nephropathy (LMN) are at substantial long-ter
136 d decline in renal function in patients with membranous nephropathy may be due to renal vein thrombos
137 actors, compared with IgAN (referent), FSGS, membranous nephropathy, membranoproliferative GN, lupus
138 ed as a surrogate for long-term prognosis in membranous nephropathy (MGN), variability in proteinuria
139 plasm-associated glomerulopathy, autoimmune (membranous nephropathy, minimal change disease) and para
140 D7A) is a target antigen identified in adult membranous nephropathy (MN) along with the major antigen
141                    Six patients with primary membranous nephropathy (MN) and eight with lupus nephrit
142                        Most newly discovered membranous nephropathy (MN) antigens have been mutually
143 ultiple autoantigens have been identified in membranous nephropathy (MN) by tissue-based proteomics.
144   Absent a remission of proteinuria, primary membranous nephropathy (MN) can lead to ESRD over many y
145                                              Membranous nephropathy (MN) can recur in kidney allograf
146 te, only individual reports of donor-derived membranous nephropathy (MN) have been described.
147 he Heymann nephritis (HN) rat model of human membranous nephropathy (MN) have shown that IgG antibodi
148 fies a new antigen responsible for secondary membranous nephropathy (MN) in a patient with mucopolysa
149                                              Membranous nephropathy (MN) is a common cause of nephrot
150                                              Membranous nephropathy (MN) is a common cause of nephrot
151                                              Membranous nephropathy (MN) is a common cause of protein
152                                              Membranous nephropathy (MN) is a common cause of protein
153                                              Membranous nephropathy (MN) is a glomerular disease that
154                                              Membranous nephropathy (MN) is a leading cause of kidney
155 Phospholipase A2 receptor (PLA2R)-associated membranous nephropathy (MN) is a leading cause of nephro
156                                              Membranous nephropathy (MN) is a leading cause of nephro
157                                              Membranous nephropathy (MN) is a major cause of nephroti
158                                              Membranous nephropathy (MN) is a pattern of injury cause
159                                              Membranous Nephropathy (MN) is a rare autoimmune cause o
160                                              Membranous nephropathy (MN) is an antibody-mediated auto
161                                      Primary membranous nephropathy (MN) is an autoimmune disease mai
162                                              Membranous nephropathy (MN) is an autoimmune kidney dise
163                                      Primary membranous nephropathy (MN) is an autoimmune kidney dise
164                                      Primary membranous nephropathy (MN) is caused by circulating aut
165                                              Membranous nephropathy (MN) is characterized by subepith
166                                              Membranous nephropathy (MN) is rare in pediatric patient
167                                              Membranous nephropathy (MN) is the most common cause of
168                                              Membranous nephropathy (MN) is the most common cause of
169                                              Membranous nephropathy (MN) is the most common cause of
170                                              Membranous nephropathy (MN) occurs due to deposition of
171                                              Membranous nephropathy (MN) results from accumulation of
172                                              Membranous nephropathy (MN) results from deposition of a
173    Drugs are an important secondary cause of membranous nephropathy (MN) with the most common drugs a
174   As recently as 2002, most cases of primary membranous nephropathy (MN), a relatively common cause o
175 A) are the two major autoantigens in primary membranous nephropathy (MN), and define two molecular su
176 ssion in two-thirds of patients with primary membranous nephropathy (MN), even after other treatments
177 xceptionally strong genetic risk factors for membranous nephropathy (MN), leading, through an unknown
178 is (FSGS), minimal change disease (MCD), and membranous nephropathy (MN), may respond well to cyclosp
179                                           In membranous nephropathy (MN), which is characterized by d
180 long been recognized as a central feature of membranous nephropathy (MN).
181 t podocyte-directed autoantibodies can cause membranous nephropathy (MN).
182 cently discovery of novel target antigens in membranous nephropathy (MN).
183 s a target for autoimmunity in patients with membranous nephropathy (MN).
184  (PLA2R) is the major autoantigen of primary membranous nephropathy (MN).
185 r in the diagnosis and monitoring of primary membranous nephropathy (MN).
186                                              Membranous nephropathy (MN, 24.96%) and IgA nephropathy
187 erosis [FSGS], minimal-change disease [MCD], membranous nephropathy [MNP], lupus nephritis [LN], and
188 ncluding IgA nephropathy and IgA vasculitis, membranous nephropathy, nephrotic syndrome, minimal chan
189 n discovery was performed comparing cases of membranous nephropathy of unknown and known type.
190 vs IgAN, ranged from 0.49 for DN to 0.92 for membranous nephropathy or ADPKD) than by lower rates of
191  and nephrotic syndrome caused by idiopathic membranous nephropathy or focal segmental glomeruloscler
192 s from patients with idiopathic or secondary membranous nephropathy or other proteinuric or autoimmun
193 s in 32 patients with FSGS, lupus nephritis, membranous nephropathy, or diabetic nephropathy.
194  glomerulonephritis, minimal change disease, membranous nephropathy, or FSGS to 3%-5% in IgA nephropa
195  20 patients with minimal change disease and membranous nephropathy (P < 0.01).
196               In a rat model of experimental membranous nephropathy (passive Heymann nephritis (PHN))
197 ive glomerulonephritis, IgA nephropathy, and membranous nephropathy), patients with systemic lupus er
198  serum samples from patients with idiopathic membranous nephropathy, patients with other glomerular d
199    Randomized trials of rituximab in primary membranous nephropathy (PMN) have not been conducted.
200                                      Primary membranous nephropathy (pMN) is a leading cause of nephr
201                                      Primary membranous nephropathy (PMN) is an autoimmune disease li
202 critical role in the pathogenesis of primary membranous nephropathy (PMN), an autoimmune kidney disea
203 t ( approximately 70%) patients with primary membranous nephropathy (pMN).
204 correlate with the immunological activity of membranous nephropathy, potentially exhibiting a more ra
205        We randomly assigned patients who had membranous nephropathy, proteinuria of at least 5 g per
206           Discovery of novel autoantigens in membranous nephropathy provides promise for development
207 ruli of NTS injured mice and passive Heymann membranous nephropathy rats.
208        All patients with PLA(2)R1-associated membranous nephropathy recognize at least two epitope re
209  cohort with anti-PLA2R1-negative idiopathic membranous nephropathy recognized a glomerular protein t
210                                              Membranous nephropathy recurs in 48% of cases threatenin
211                                              Membranous nephropathy recurs in approximately 40% of pa
212 lophosphamide in the Treatment of Idiopathic Membranous Nephropathy (RI-CYCLO), NCT03018535.
213 captures the discussion that occurred at the Membranous Nephropathy Scientific Workshop.
214                    Nephrotic syndrome due to membranous nephropathy should be recognized as an idiosy
215 y, serum from patients with NCAM1-associated membranous nephropathy showed reactivity to NCAM1 recomb
216 ents (70%) with idiopathic but not secondary membranous nephropathy specifically identified a 185-kD
217 g that it can release the ectodomains of the membranous nephropathy target antigens phospholipase A2
218 D risk was significantly higher for FSGS and membranous nephropathy than for presumed minimal change
219  shown in phospholipase A2 receptor positive membranous nephropathy that known antibodies can be dete
220 lomerulopathies minimal-change nephrosis and membranous nephropathy, there is an increase in Shp2 pho
221 red with PLA2R- and THSD7A-positive cases of membranous nephropathy, there was a greater proportion o
222 e graft contributes to recurrence of primary membranous nephropathy through the disease susceptibilit
223 use of immunosuppressive drugs in idiopathic membranous nephropathy to patients at the highest risk o
224  of immune deposit formation in experimental membranous nephropathy to the role of a microRNA in FSGS
225      In patients with secondary (autoimmune) membranous nephropathy, two novel proteins, Exostosin 1
226 eterologous mouse model of THSD7A-associated membranous nephropathy, various melanocortin agents, inc
227 The mean age of patients with NELL1-positive membranous nephropathy was 66.8 years, with a slight mal
228 n groups into five subgroups, interestingly, membranous nephropathy was the most common pathologic ty
229 n nephritis, a complement-dependent model of membranous nephropathy, was examined.
230 nts with newly diagnosed PLA(2)R1-associated membranous nephropathy, we investigated the clinical rol
231  with a nephrotic syndrome and biopsy-proven membranous nephropathy were administered a 3 to 6-month
232 while taking an NSAID and if other causes of membranous nephropathy were excluded and a rapid remissi
233 tibodies in serum samples from patients with membranous nephropathy were mainly IgG4, the predominant
234       In contrast, MC5R knockout exacerbated membranous nephropathy, while abolishing the beneficial
235  were serially evaluated in 15 patients with membranous nephropathy who exhibited relapsing nephrosis
236           We describe a 63-year-old man with membranous nephropathy who underwent a kidney transplant
237 samples from the 74 patients with idiopathic membranous nephropathy who were seropositive for anti-PL
238 pholipase A(2) receptor-associated recurrent membranous nephropathy with circulating anti-Phospholipa
239 s renal function in patients with idiopathic membranous nephropathy with declining renal function.
240  a kidney transplant and developed recurrent membranous nephropathy with fine granular co-localizatio
241 y-based minimal change nephropathy, FSGS, or membranous nephropathy, with 94% sensitivity and 92% PPV
242 y in this cohort of patients with idiopathic membranous nephropathy yielded favorable outcomes while

 
Page Top